SLC5A2 and type 2 diabetes mellitus: Owing to substantial cost difference vs SGLT2 inhibitors, long-standing safety record, tolerability, and beneficial metabolic profile, metformin may still be the preferred choice as a first-line antihyperglycemic agent in type 2 diabetes.